/Announcement of Harbin Pharmaceutical Group Co., Ltd. on the expected daily related transactions in 2026

NEWS

Announcement of Harbin Pharmaceutical Group Co., Ltd. on the expected daily related transactions in 2026

Shanghai Stock Exchange

2026/01/27

Securities code: 600664 Securities abbreviation: Harbin Pharmaceutical Group Co., Ltd. Number: 2026-004 Harbin Pharmaceutical Group Co., Ltd.

Announcement on the expected daily related transactions in 2026

The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents. Important content reminder:

 Whether it needs to be submitted to the shareholders’ meeting for review: No

 The impact of daily related transactions on listed companies: The company's daily related transactions in 2026 are in compliance with the relevant provisions of laws, regulations and systems. The company's main business will not become dependent on related parties due to the occurrence of related transactions, will not affect the company's independence, and will not harm the interests of the company and all shareholders.

1. Basic situation of daily related transactions

(1) Review procedures for the performance of daily related transactions

The company's 23rd meeting of the 10th board of directors held on January 26, 2026 reviewed and approved the "Proposal on the Company's Estimated Daily Related Transactions in 2026" (5 votes in favor, 0 votes against, 0 abstentions, related directors Ms. Hu Xiaoping, Mr. Sun Zhifeng, Mr. Yin Shiwei, and Mr. Liu Mo abstained from voting).

Before the board of directors' review, the company held a special meeting of independent directors on January 21, 2026. After reviewing the company's daily related transactions, all independent directors of the company formed the following opinions: the company's daily related transactions that occurred in 2025 were fair and reasonable, and did not harm the interests of the company and all shareholders. The company's daily related transactions expected to occur in 2026 are required for the company's normal operations and management. The related transactions follow the principles of fair, just and reasonable pricing, will not harm the interests of the company and all shareholders, and will not affect the company's independence. The independent directors unanimously agreed to submit the above proposal to the company's board of directors for review.

1/7

(2) Estimation and execution of daily related transactions in 2025

Unit: RMB 10,000 Estimated amount and actual related transaction category Name of related party Estimated amount in 2025 Actual amount in 2025 Reasons for the large difference in actual amount

Harbin Pharmaceutical Group Biological Vaccine Co., Ltd. 238.00 186.28 Sales of products to related parties

Harbin Pharmaceutical Group Co., Ltd. 9.00 7.53 products, commodities

Subtotal 247.00 193.81

Harbin Pharmaceutical Group Biological Vaccine Co., Ltd. - 41.49 Providing services to related parties Heilongjiang Harbin Pharmaceutical Charity Foundation 0.10 0.04

Subtotal 0.10 41.53 Purchase of products from related parties

products, merchandise, pay special GNCHOLDINGS,LLC 5,786.00 5,227.44 license fees, etc.

Donate to related parties Heilongjiang Harbin Pharmaceutical Charity Foundation 37.00 17.00

Total 6,070.10 5,479.78

Note: The actual amount incurred by the company in 2025 in the above table has not been audited, and the final amount of related transactions is subject to the data disclosed in the company's 2025 annual report.

(3) Estimated amount and types of daily related transactions in 2026

Unit: RMB 10,000 The estimated amount from the beginning of this year to the same period in 2025

The reason for the large difference between the date of this preview and the related party and the actual amount of related transactions in the previous year.

430.83 0.0261 0.36 186.28 0.0116

Ltd.

Sales to related parties

Harbin Pharmaceutical Group Co., Ltd. 10.00 0.0006 - 7.53 0.0005Products, commodities

Subtotal 440.83 0.0267 0.36 193.81 0.0121Provide Harbin Pharmaceutical Group Biovaccine to related parties

105.00 0.0064 - 41.49 0.0026 Labor Service Co., Ltd.

2/7

As of the beginning of this year, the estimated amount of this transaction accounts for 10% of the same category. The actual amount in 2025 will account for 10% of the same category.

Type of related transaction between the date of this preview and the related party and the actual amount of related party issued in the previous year. Name of related person. Actual amount of business. Actual amount of business. Comparison of the difference between the cumulative amount of occurrence (%). Amount (%)

Purchasing from related parties due to large transaction amount

PRODUCTS, MERCHANDISE, GNCHOLDINGS,

4,632.07 5.3133 - 5,227.44 6.1442 Payment to Franchise LLC

Fees, etc.

Heilongjiang Province Harbin Pharmaceutical Public Welfare

Donation to related persons 15.00 50.0000 - 17.00 56.1114

Foundation

Total 5,192.90 0.36 5,479.74

2. Introduction to related parties and related relationships

(1) Name of related party: Harbin Pharmaceutical Group Biological Vaccine Co., Ltd.

1.Basic situation

Legal representative: Liu Hongbin

Registered capital: RMB 93.88 million

Registered address: No. 277 Haping Road, Xiangfang District, Harbin

Main business: Engage in business within the scope approved by the veterinary drug production license, veterinary drug business license, and veterinary biological products import license.

Relationship with the company

Harbin Pharmaceutical Group Biological Vaccine Co., Ltd. and the Company are related parties controlled by the same parent company.

Analysis of the execution status and performance capabilities of similar related-party transactions in the previous period

According to its financial status and credit standing, the related party has a good reputation, has performed well in similar related-party transactions in the previous period, and has sufficient performance capabilities.

(2) Related parties: Harbin Pharmaceutical Group Co., Ltd.

1.Basic situation

3/7

Legal representative: Zhang Yichen

Registered capital: RMB 4,352.94 million

Unified social credit code: 91230100127040288Q

Date of establishment: 1989-05-13

Registered address: No. 68, Limin West Fourth Street, Limin Development Zone, Harbin

Main business: The state allows foreign investment in fields to carry out investment business in accordance with the law, and provides its invested enterprises with technical support in the process of product production, sales and market development, employee training, internal personnel management and other services, assists its invested enterprises in seeking loans and providing guarantees, etc.

Relationship with the company

Harbin Pharmaceutical Group Co., Ltd. is the controlling shareholder of the company, holding 46.58% of the company’s shares.

Analysis of the execution status and performance capabilities of similar related-party transactions in the previous period

(3) Related party name: GNC HOLDINGS, LLC

1.Basic situation

Registered address: Delaware

Main business: R&D and sales of various vitamins, herbal and mineral dietary nutritional supplements, sports and fitness supplements, weight management products and other health products and personal care products. It also sells third-party brand products through its own sales channels.

Relationship with the company

GNC HOLDINGS, LLC and the Company are related parties controlled by the same parent company. 3. Analysis of the execution status and performance capabilities of similar related-party transactions in the previous period

4/7

(4) Name of related party: Heilongjiang Harbin Pharmaceutical Charity Foundation

1.Basic situation

Registered address: No. 7, Qunli Avenue, Daoli District, Harbin City

Business scope: Carry out on-site medical security and assistance services at public events; carry out popular science lectures, academic research, education and training, project cooperation, public welfare forums, etc. in the fields of civil health, disease relief and medical treatment; carry out public welfare and charity activities that comply with legal provisions, such as poverty alleviation, elder care and orphan care, child support and weak support, disability care, epidemic prevention and disaster relief, medical and educational assistance, volunteer services, etc. 2. Relationship with related parties

Heilongjiang Province Harbin Pharmaceutical Charity Foundation is a non-public foundation funded and initiated by Harbin Pharmaceutical Group Co., Ltd. and directly managed by the Heilongjiang Provincial Department of Civil Affairs. The company's senior managers serve as the legal representatives of the Heilongjiang Harbin Pharmaceutical Charity Foundation and therefore constitute a related relationship.

Analysis of the execution status and performance capabilities of similar related-party transactions in the previous period

3. Main contents and pricing policies of related-party transactions

(1) Main contents of transaction

The daily related transactions expected to occur between the company and related parties in 2026 are mainly the company's daily operating activities. The transaction contents include: selling products and commodities produced or operated by the company to related parties such as Harbin Pharmaceutical Group Bio-Vaccine Co., Ltd.; purchasing various products and commodities produced or operated by GNC HOLDINGS, LLC, paying royalties, etc.; providing labor services to Harbin Pharmaceutical Group Bio-Vaccine Co., Ltd.; donating various products and commodities produced or operated by the company to the Heilongjiang Province Harbin Pharmaceutical Charity Foundation.

5/7

(2) Pricing policy

Related transactions between the company and the above-mentioned related parties are conducted on the principles of voluntariness, equality, mutual benefit and fairness.

(3) Pricing basis

Purchasing products: The company reserves the right to choose other third parties to ensure that related parties provide products to the company at normal prices. Both parties negotiate pricing based on the market price of similar products.
Sales of products: The company sells products to related parties at the price sold to other independent third parties.
Provision of labor services to related parties: The company provides labor services to related parties at the price of providing similar services to other independent third parties.
Donated products: The company determines the transaction price based on the sales price of the materials sold by the donor, the government guidance price, the price of similar or similar products on well-known large e-commerce platforms, etc.

4. Purpose of related transactions and impact on the company

(1) Necessity and continuity of transaction

In order to meet the company's daily production and operation needs, the company carries out sales, procurement and other related-party transactions with related parties. The above-mentioned transactions constitute an integral part of the company's operating costs, revenue and profits. Harbin Pharmaceutical Group Biological Vaccine Co., Ltd. and Harbin Pharmaceutical Group Co., Ltd. are the sales customers of the company's products; GNC HOLDINGS, LLC is the supplier and operating licensee of the company's GNC products, ensuring the stability of related product supply channels; the company donates various products and commodities produced or operated by the company to the Heilongjiang Province Harbin Pharmaceutical Charity Foundation, which is a concrete manifestation of the company's active social responsibility and helps to further enhance the company's brand influence.

(2) Fairness of transaction

The above-mentioned daily related transactions follow the general business principles of equality, mutual benefit and equal compensation.

6/7

The price is determined according to the market price, and the pricing is fair and reasonable. The above-mentioned daily related transactions do not harm the interests of the company and shareholders, especially small and medium-sized shareholders, and are in the overall interests of the company and its shareholders.

(3) The impact of the transaction on the company’s independence

The company's daily related transactions comply with the relevant provisions of laws, regulations and systems. The company's main business will not become dependent on related parties due to the above related transactions, nor will it affect the company's independence, nor will it harm the interests of the company and all shareholders.

Announcement is hereby made.

Board of Directors of Harbin Pharmaceutical Group Co., Ltd. January 27, 2026

7/7